Synthesis of Best-Seller Drugs by Vardanyan Ruben & Hruby Victor

Author:Vardanyan, Ruben & Hruby, Victor [Vardanyan, Ruben & Hruby, Victor]
Language: eng
Format: epub
Tags: Science, Chemistry, Organic, Medical, Pharmacology
ISBN: 9780124114920
Google: DgcujgEACAAJ
Amazon: 012411492X
Publisher: Academic Press
Published: 2016-01-08T04:00:31.000940+00:00

278.

Gaboriaud-Kolar, N.; Skaltsounis, A.-L. Glycogen phosphorylase inhibitors: a patent review. Expert Opin. Ther. Pat. 2013, 23 (8), 1017–1032.

279. Somsak, L.; Czifrak, K.; Toth, M.; Bokor, E.; Chrysina, E. D.; Alexacou, K.-M.; Hayes, J. M.; Tiraidis, C.; Lazoura, E.; Leonidas, D. D. New inhibitors of glycogen phosphorylase as potential antidiabetic agents. Curr. Med. Chem. 2008, 15 (28), 2933–2983.

280. Treadway, J. L.; Mendys, P.; Hoover, D. J. Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus. Expert Opin. Invest. Drugs 2001, 10 (3), 439–454.

281. Klabunde, T.; Wendt, K. U.; Kadereit, D.; Brachvogel, V.; Burger, H.-J.; Herling, A. W.; Oikonomakos, N. G.; Kosmopoulou, M. N.; Schmoll, D.; Sarubbi, E.; Von Roedern, E.; Schoenafinger, K.; Defossa, E. Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. J. Med. Chem. 2005, 48 (20), 6178–6193.

458 Synthesis of Best-Seller Drugs

282. Defossa, E.; Kadereit, D.; Klabunde, T.; Burger, H-J.; Herling, A.; Wendt, K-U.; Von Roedern, E; Schoenafinger, K., Preparation of N-[(phenylamino)carbonyl]benzamides as glycogenphos-phorylase-A inhibitors for the treatment of diabetes, WO 2004007437 (2004).

283. Grasso, P. Novel approaches to the treatment of obesity and type 2 diabetes mellitus: bioactive leptin-related synthetic peptide analogs. Recent Pat. Endocr., Metab. Immune Drug Discovery 2011, 5 (3), 163–175.

284. Coppari, R.; Bjorbaek, C. Leptin revisited: its mechanism of action and potential for treating diabetes. Nat. Rev. Drug Discovery 2012, 11 (9), 692–708.

285. Pal, M. Recent advances in glucokinase activators for the treatment of type 2 diabetes. Drug Discovery Today 2009, 14 (15/16), 784–792.

286. Sarabu, R.; Berthel, S. J.; Kester, R. F.; Tilley, J. W. Glucokinase activators as new type 2

diabetes therapeutic agents. Expert Opin. Ther. Pat. 2008, 18 (7), 759–768.

287. Meininger, G. E.; Scott, R.; Alba, M.; Shentu, Y.; Luo, E.; Amin, H.; Davies, M. J.; Kaufman, K. D.; Goldstein, B. J. Effects of MK-(0941), a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 2011, 34 (12), 25602566.

288. Grimsby, J.; Sarabu, R.; Corbett, W. L.; Haynes, N.-E.; Bizzarro, F. T.; Coffey, J. W.; Guertin, K. R.; Hilliard, D. W.; Kester, R. F.; Mahaney, P. E.; Marcus, L.; Qi, L.; Spence, C. L.; Tengi, J.; Magnuson, M. A.; Chu, C. A.; Dvorozniak, M. T.; Matschinsky, F. M.; Grippo, J. F.

Allosteric activators of glucokinase: potential role in diabetes therapy. Science (Washington, DC, U. S.) 2003, 301 (5631), 370–373.

289. Futamura, M.; Hosaka, H.; Kadotani, A.; Shimazaki, H.; Sasaki, K.; Ohyama, S.; Nishimura, T.; Eiki, J.; Nagata, Y. An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism. J. Biol. Chem. 2006, 281 (49), 37668–37674.

290. Fyfe, M. C. T.; White, J. R.; Taylor, A.; Chatfield, R.; Wargent, E.; Printz, R. L.; Sulpice, T.; McCormack, J. G.; Procter, M. J.; Reynet, C.; Widdowson, P. S.; Wong-Kai-In, P. Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions. Diabetologia 2007, 50 (6), 1277–1287.

291. Daniewski, A. R.; Liu, W.; Radinov, R. N., Process for preparation of piragliatin, WO

2007115968 (2007).

292. Efanov, A. M.; Barrett, D. G.; Brenner, M. B.; Briggs, S. L.; Delaunois, A.

Download

Copyright Disclaimer:
This site does not store any files on its server. We only index and link to content provided by other sites. Please contact the content providers to delete copyright contents if any and email us, we'll remove relevant links or contents immediately.